<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): November 3, 2000
AXYS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-22788 22-2969941
---------------------------- ---------------- ----------------------
(State or other jurisdiction (Commission File (I.R.S. Employer
of Incorporation) Number) Identification Number)
180 Kimball Way
South San Francisco, CA 94080
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(650) 829-1000
---------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits: The following exhibits are filed as part of this Report.
20.1 Press Release, dated November 3, 2000, of Axys Pharmaceuticals,
Inc.
ITEM 9. REGULATION FD DISCLOSURE
On November 3, 2000, Axys Pharmaceuticals, Inc. (the "Company") issued a press
release to ensure full dissemination of comments made by the Company during its
third quarter, 2000 Analyst conference call. Disclosed in the press release
were: 1) if the results of the current Phase II clinical trial in ulcerative
colitis collaborate the interim data, a registration study could be anticipated
in 2001. 2) The Company's Cathepsin K research program with Merck and the
company's Cathepsin S research program with Aventis were moving toward the
nomination of IND candidates for the treatment of osteoperosis and asthma,
respectively, in the next several months, and 3) the company projects a loss of
$0.12 to $0.18 on a per share basis for the full year 2000. The press release is
attached hereto as Exhibit 20.1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrants have duly caused this report to be signed on their behalf by the
undersigned hereunto duly authorized.
Dated: November 3, 2000
AXYS PHARMACEUTICALS, INC.
By: /s/ William J. Newell
---------------------------------
William J. Newell
Senior Vice President
<PAGE> 3
EXHIBIT INDEX
Exhibits Description
-------- -----------
20.1 Press Release, dated November 3, 2000, of Axys Pharmaceuticals,
Inc.
